8:20 am Morning Coffee & Light Breakfast
8:50 am Chair’s Opening Remarks
Supercharging Neoantigen Vaccine Platforms Towards Patients in Need by Optimising Design & Delivery for More Potent Therapies
9:00 am Bringing Novel Class of Vaccine Targets into Development – Camyopeptides Derived from Tumour-Specific IncRNAs
Synopsis
- Results from the profiling of over 1500+ tumour biopts and neoantigen landscapes
- First glance at immunological responses revealing first-in-class potential of shared tumor targets
- Designing the mRNA-LNP cancer vaccine
9:30 am Optimising RNA/DNA-based Vaccine Design by Identifying Key Characteristics to Ensure Success of the Therapy
Synopsis
- How to improve immune responses by targeting epitopes to antigen presenting cells
- Impact of neoepitope arrangement on immunogenicity and expression/secretion
- How to effectively compile the sequences, is it more effective to split the load or to add all the sequences in one molecule?
10:00 am Design of Viral Vectored Vaccines Targeting Multiple Tumour Neoantigens to Elicit Potent & Effective Anti-tumour Immune Response
Synopsis
- Design of a potent heterologous prime/boost vaccination platform based on viral vectors (non-human Great Ape Adenovirus and MVA) encoding an unprecedented number of tumour neoantigens
- Demonstrating induction of strong and high-quality T cell immune response in vaccinated patients
- Dissecting the contribution of vaccine-induced T cells to clinical responses
10:30 am An AI Platform for Designing Personalized Neoantigen Vaccines Which Induce Polyepitopic Immune Responses
Synopsis
- Overview of a unique neoantigen discovery AI platform which integrates diverse experimental and prediction evidence
- Evaluating the immunogenicty of predicted neoantigens in a preclinical setting
- Demonstrating the induction of long-lasting, polyepitopic T-cell responses from personalized neoantigen vaccines in the ongoing TG4050 clinical trial
11:00 am Morning Networking Break
Illuminating Shared Neoantigen Therapies to Induce More Durable & Robust Immunity in a Larger Patient Population
12:00 pm KRAS Mutation-Specific TCR-T Cells are Empowered for Improved Multi-Functionality & Durability by Inclusion of a Costimulatory Switch Protein
Synopsis
- Generation of 3S TCRs from naïve repertoires of healthy donors that recognize KRASspecific mutations (mKRAS) display high specificity, high sensitivity and an excellent safety profile in recognition of mKRAS-expressing tumour cells
- Co-expression of a PD1-41BB Costimulatory Switch Protein (CSP) armors TCR-T cells against PD-L1-mediated inhibition and enhances multiple cellular functions through intracellular activation of the 41BB costimulatory pathway, enabling TCR-T cells to function better in a hostile tumour microenvironment
- Our automated method of producing enriched CD8+ TCR-T cells yields Drug Products with enhanced capacity to proliferate and persist upon repeated encounter with PD-L1- expressing tumour cells, supporting important parameters associated with durability
12:30 pm Neoepitopes Cancer Vaccine Monotherapy Positive Efficacy Randomized Phase 3 results in Non-Small Cell Lung Cancer with Resistance to Immunotherapy
Synopsis
- Tedopi is a tumour-specific activating immunotherapy based on highly-selected and optimized tumour neoepitopes
- Positive clinical efficacy of Tedopi versus chemotherapy in a randomized Phase III trial in Non-Small Cell Lung Cancer in patients with secondary resistance after failure of checkpoint inhibitors: Significantly better survival: 44% overall survival at 1-year, versus 27% with chemotherapy; Significantly better safety profile: 3-fold less severe Grade 3-5 adverse events and significantly better quality of life.
1:00 pm Targeting Neoantigens with Invariant Natural Killer T Cells
Synopsis
- MiNK therapeutics is developing iNKT-based allogeneic cell therapy products for cancer. Invariant Natural Killer T cells (iNKT) recognize glycolipids presented on CD1d through their invariant TCR.
- iNKT cells can be engineered to stably express a 2nd TCR, and both TCRs are fully functional
- We are developing a portfolio of phospho-peptide neoantigen-specific TCRs for iNKT-based applications
1:30 pm Lunch & Networking
Optimising Combination Therapies by Deep Diving into Mechanism of Action & Combination Strategies for More Successful, Effective & Safer Therapeutics
2:30 pm Panel Discussion: Evaluating Different Combination Strategies to Develop More Effective Cancer Treatments for Curing the Patients in Need
Synopsis
- Which of the current state of the art immunotherapies are likely to combine well with neoantigen therapies?
- Beyond checkpoint inhibitors, what combinations seem the most promising?
- Are there certain combinations which work better for different stages of cancer?
- Discussing combining neoantigen therapies with PD-L1 therapies, chemotherapies and immunoglobins.
3:30 pm Afternoon Networking Break
4:00 pm Delving into the Mechanism of Action of Neoantigen Antibodies to Aid the Development of Highly Effective Combination Strategy Towards More Successful Therapies
Synopsis
- What is the mechanism of action of a neoantigen antibody being used in combination?
- How to effectively use the neoantigen antibody, should it be applied before the checkpoint inhibitor or after?
- Would it be beneficial to combine with more than one other approach?
4:30 pm Multitargeted Self-Replicating RNA for Off-The-Shelf Cancer Precision Immunotherapeutics
Synopsis
- Replicate Bioscience’s self-replicating RNA platform supports a unique and powerful approach to preventing and reversing the emergence of common acquired resistance mutations
- Using multigenic self-replicating RNA we have created precision immunotherapeutics that can be dosed in combination with SOC approved cancer agents, thus maintaining selective pressure on the tumour
- Mechanistically, the combination of the Replicate immunotherapy and the SOC creates a lose-lose situation wherein wild-type tumour clones are controlled by the SOC treatment and resistance mutant positive clones die by the precision immunotherapeutic. We term this synthetic immune lethality